Merck Corrects Zocor, Vioxx Impact On Gross Margins
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says fourth quarter product gross margin is expected to be about 77% instead of the 75% previously reported. The guidance excludes adjustments related to the Vioxx withdrawal.